JP2019533715A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533715A5 JP2019533715A5 JP2019525021A JP2019525021A JP2019533715A5 JP 2019533715 A5 JP2019533715 A5 JP 2019533715A5 JP 2019525021 A JP2019525021 A JP 2019525021A JP 2019525021 A JP2019525021 A JP 2019525021A JP 2019533715 A5 JP2019533715 A5 JP 2019533715A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutical composition
- ldl
- pcsk9
- reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023019926A JP2023071715A (ja) | 2016-11-14 | 2023-02-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
| JP2025033900A JP2025102770A (ja) | 2016-11-14 | 2025-03-04 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662421685P | 2016-11-14 | 2016-11-14 | |
| US62/421,685 | 2016-11-14 | ||
| US201762471874P | 2017-03-15 | 2017-03-15 | |
| US62/471,874 | 2017-03-15 | ||
| US201762515117P | 2017-06-05 | 2017-06-05 | |
| US62/515,117 | 2017-06-05 | ||
| US201762581244P | 2017-11-03 | 2017-11-03 | |
| US62/581,244 | 2017-11-03 | ||
| US201762584600P | 2017-11-10 | 2017-11-10 | |
| US62/584,600 | 2017-11-10 | ||
| PCT/US2017/061346 WO2018089912A2 (en) | 2016-11-14 | 2017-11-13 | Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023019926A Division JP2023071715A (ja) | 2016-11-14 | 2023-02-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019533715A JP2019533715A (ja) | 2019-11-21 |
| JP2019533715A5 true JP2019533715A5 (enExample) | 2020-12-24 |
Family
ID=60484496
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019525021A Pending JP2019533715A (ja) | 2016-11-14 | 2017-11-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
| JP2023019926A Pending JP2023071715A (ja) | 2016-11-14 | 2023-02-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
| JP2025033900A Pending JP2025102770A (ja) | 2016-11-14 | 2025-03-04 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023019926A Pending JP2023071715A (ja) | 2016-11-14 | 2023-02-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
| JP2025033900A Pending JP2025102770A (ja) | 2016-11-14 | 2025-03-04 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20200368350A1 (enExample) |
| EP (1) | EP3538149A2 (enExample) |
| JP (3) | JP2019533715A (enExample) |
| KR (2) | KR20240096648A (enExample) |
| CN (1) | CN110234350A (enExample) |
| AU (2) | AU2017356219A1 (enExample) |
| BR (1) | BR112019009726A2 (enExample) |
| CA (1) | CA3043700A1 (enExample) |
| CL (2) | CL2019001304A1 (enExample) |
| CO (1) | CO2019004814A2 (enExample) |
| IL (2) | IL326501A (enExample) |
| JO (1) | JOP20190112A1 (enExample) |
| MA (1) | MA46758A (enExample) |
| MX (3) | MX2019005627A (enExample) |
| TN (1) | TN2019000156A1 (enExample) |
| WO (1) | WO2018089912A2 (enExample) |
| ZA (1) | ZA201902975B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| EP3169710A1 (en) * | 2014-07-14 | 2017-05-24 | Amgen Inc. | Crystalline antibody formulations |
| JOP20190215A1 (ar) | 2017-03-24 | 2019-09-19 | Ionis Pharmaceuticals Inc | مُعدّلات التعبير الوراثي عن pcsk9 |
| JP2021533190A (ja) * | 2018-07-31 | 2021-12-02 | タン ウェンTAN, Wen | ＬＤＬコレステロールの細胞内クリアランスを増強しかつスタチンとの併用療法で効力を高めかつ副作用を減らすための、カルバメートβフェニルエタノールアミン類似体の新規使用法 |
| EA202191890A1 (ru) | 2019-01-18 | 2022-02-03 | Астразенека Аб | Ингибиторы pcsk9 и способы их применения |
| US11248001B2 (en) | 2019-01-18 | 2022-02-15 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| WO2021012074A1 (en) * | 2019-07-19 | 2021-01-28 | Ebay Inc. | Sample delta monitoring |
| CN112656792B (zh) * | 2021-01-26 | 2022-07-05 | 首都医科大学宣武医院 | 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101484588B (zh) | 2006-05-11 | 2013-11-06 | 阿尔尼拉姆医药品有限公司 | 抑制pcsk9基因表达的组合物和方法 |
| AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Ｐｃｓｋ９拮抗劑類 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US9493774B2 (en) * | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
| AU2010260148A1 (en) | 2009-06-15 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Lipid formulated dsRNA targeting the PCSK9 gene |
| AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| BR112013015687A2 (pt) | 2010-12-22 | 2016-10-11 | Genentech Inc | anticorpo anti-pcsk9 ou um fragmento de anticorpo que se liga a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar um anticorpo anti-pcsk9, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito e método de tratamento de hipercolesterolemia em um sujeito |
| KR20140006022A (ko) | 2011-02-11 | 2014-01-15 | 아이알엠 엘엘씨 | Pcsk9 길항제 |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AR087715A1 (es) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
| PL3119810T3 (pl) * | 2014-03-17 | 2024-07-15 | Sanofi Biotechnology | Sposoby obniżania ryzyka sercowo-naczyniowego |
| SG11201705444QA (en) * | 2015-01-09 | 2017-07-28 | Global Genomics Group Llc | Blood based biomarkers for diagnosing atherosclerotic coronary artery disease |
-
2017
- 2017-06-16 JO JOP/2019/0112A patent/JOP20190112A1/ar unknown
- 2017-11-13 KR KR1020247018411A patent/KR20240096648A/ko active Pending
- 2017-11-13 CN CN201780083280.9A patent/CN110234350A/zh active Pending
- 2017-11-13 EP EP17805364.1A patent/EP3538149A2/en active Pending
- 2017-11-13 MA MA046758A patent/MA46758A/fr unknown
- 2017-11-13 WO PCT/US2017/061346 patent/WO2018089912A2/en not_active Ceased
- 2017-11-13 BR BR112019009726-0A patent/BR112019009726A2/pt unknown
- 2017-11-13 KR KR1020197016872A patent/KR20190085963A/ko not_active Ceased
- 2017-11-13 AU AU2017356219A patent/AU2017356219A1/en not_active Abandoned
- 2017-11-13 IL IL326501A patent/IL326501A/en unknown
- 2017-11-13 JP JP2019525021A patent/JP2019533715A/ja active Pending
- 2017-11-13 TN TNP/2019/000156A patent/TN2019000156A1/en unknown
- 2017-11-13 MX MX2019005627A patent/MX2019005627A/es unknown
- 2017-11-13 CA CA3043700A patent/CA3043700A1/en active Pending
- 2017-11-13 US US16/348,653 patent/US20200368350A1/en active Pending
-
2019
- 2019-05-12 IL IL266579A patent/IL266579A/en unknown
- 2019-05-13 ZA ZA2019/02975A patent/ZA201902975B/en unknown
- 2019-05-13 CL CL2019001304A patent/CL2019001304A1/es unknown
- 2019-05-13 CO CONC2019/0004814A patent/CO2019004814A2/es unknown
- 2019-05-14 MX MX2025002106A patent/MX2025002106A/es unknown
- 2019-05-14 MX MX2024000805A patent/MX2024000805A/es unknown
-
2020
- 2020-11-18 CL CL2020002993A patent/CL2020002993A1/es unknown
-
2023
- 2023-02-13 JP JP2023019926A patent/JP2023071715A/ja active Pending
-
2024
- 2024-12-06 AU AU2024278180A patent/AU2024278180A1/en active Pending
-
2025
- 2025-03-04 JP JP2025033900A patent/JP2025102770A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Keene et al. | Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients | |
| IL277127B1 (en) | Using pcsk9 tracking to reduce cardiovascular risk | |
| NO20073456L (no) | Omega-3 fettsyrer og dyslipidemisk middel for lipidbehandling | |
| HRP20250797T1 (hr) | Postupci za liječenje pacijenata s obiteljskom hiperkolesterolemijom | |
| JP2017528427A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2017506626A5 (enExample) | ||
| JP2015518897A5 (enExample) | ||
| WO2009022821A3 (en) | Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same | |
| KR20160043117A (ko) | 가속화된 경화반 퇴행을 위한 조성물 및 치료방법 | |
| A Mangiafico et al. | Medical treatment of critical limb ischemia: current state and future directions | |
| Constance et al. | Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects≥ 65 years | |
| Gertner | Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome | |
| JP4839309B2 (ja) | 血栓症治療剤 | |
| Teixeira | Scientific basis of the homeopathic healing principle in modern pharmacology | |
| Polska | Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3,227 patients | |
| WO2008121461A3 (en) | Vaccine for activating helper function of cd8+ tcells | |
| Poli et al. | Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: analysis of SEAS and JUPITER trials | |
| Cinquegrani et al. | MRSA bacteremia and new-onset aortic and mitral regurgitation: a pernicious and tricky association | |
| WO2019216313A1 (ja) | 心血管疾患に有用な医薬 | |
| AU2009327374A1 (en) | Treatment of major adverse cardiac events and acute coronary syndrome using secretory phospholipase A2 (sPLA2) inhibitor or sPLA2 inhibitor combination therapies | |
| Pham | Lipid-lowering therapy after acute coronary syndrome: new developments | |
| US20080146534A1 (en) | Pharmaceutical composition for reducing the risks associated with cardiovascular and cerebrovascular diseases | |
| Leon et al. | Association of inclisiran initiation on oral antilipemic therapy discontinuation rates | |
| Takamatsu et al. | A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma |